Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.

Rhea-AI Summary

Oppenheimer (NYSE: OPY) announced on Dec. 8, 2025 that Kostas Biliouris, Ph.D., joined as Managing Director on its Biotech Research Team, based in New York and reporting to William Bird.

Biliouris previously worked at BMO Capital Markets covering genetic medicines, was a VP in biotech research at Morgan Stanley, and held drug development and product strategy roles at Novartis. His background includes a Ph.D. in biochemical engineering and scientific publications with Biogen, Ionis, Merck, Novartis, and the FDA. The firm said the hire strengthens Oppenheimer's long-standing healthcare and biotech research franchise and expands coverage across genetic medicines and related sectors.

News Market Reaction – OPY

+0.19%

1 alert

+0.19% News Effect

On the day this news was published, OPY gained 0.19%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $86.52 Vol: Volume 57,529 is above th...

high vol

$86.52 Last Close

Volume Volume 57,529 is above the 20-day average of 36,389, indicating elevated trading activity ahead of this leadership announcement. high

Technical Price at $67.87 is trading above the 200-day MA of $66.50, while still 15.15% below the 52-week high of $79.99.

Peers on Argus

Sector peers show mixed moves, with HIVE down 5.02%, BTBT down 5.13%, and others...

1 Up

Sector peers show mixed moves, with HIVE down 5.02%, BTBT down 5.13%, and others like SWIN up 3.8%. Momentum scanner only flags CANG up 8.26% with no news, suggesting this Oppenheimer biotech-research hire is more company-specific than part of a broad sector trend.

Historical Context

5 past events · Latest: Nov 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 17	Leadership appointment	Positive	-4.1%	Appointed Keith Peterson as Head of Cash Equity Sales and Trading.
Oct 31	Quarterly earnings	Neutral	+0.7%	Reported Q3 2025 results with higher revenue but lower EPS year over year.
Oct 29	Leadership appointment	Positive	-1.4%	Hired Guy T. Logan as MD, Head of Infrastructure & Mid-Atlantic Region.
Oct 06	Leadership appointment	Positive	+0.2%	Named James Yoo MD in Healthcare Equity Capital Markets Investment Banking.
Sep 30	Platform expansion	Positive	-2.6%	Expanded CAPS to a comprehensive multi-asset custody and prime platform.

Pattern Detected

Recent strategic and personnel announcements have often seen muted or negative next-day price reactions, even when the news highlights platform expansion or senior hires.

Recent Company History

Over the last few months, Oppenheimer has focused on expanding key franchises and leadership depth. Hires such as heads of Cash Equity Sales and Trading and Public Finance, plus a Managing Director for Healthcare Equity Capital Markets, underscore efforts to grow equities, healthcare, and public finance capabilities. Platform initiatives like the CAPS expansion and solid Q3 2025 revenue growth to $424.4M frame today’s biotech research team hire as another step in broadening its healthcare and capital markets footprint.

Market Pulse Summary

This announcement adds a senior biotech-focused Managing Director to Oppenheimer’s research team, re...

Analysis

This announcement adds a senior biotech-focused Managing Director to Oppenheimer’s research team, reinforcing one of its longest-standing healthcare franchises. It follows earlier moves to strengthen healthcare equity capital markets and expand platforms like CAPS. Investors may track how expanded biotech coverage and relationships influence capital markets activity and advisory revenue, while also monitoring expense trends and the contribution of healthcare-related initiatives to overall results.

Key Terms

genetic medicines, biochemical engineering, securities analysis

3 terms

genetic medicines medical

"where he was a Director, mainly covering the genetic medicines space."

Genetic medicines are treatments that work by changing, replacing, or reprogramming a person’s genes or the instructions those genes send, with the goal of preventing or curing disease rather than just easing symptoms. For investors, they matter because they can offer transformative, often one-time therapies that command high prices and durable outcomes, but they also carry long development timelines, regulatory scrutiny and complex manufacturing risks — like backing a high-reward, high-risk technology startup.

biochemical engineering medical

"His background includes a Ph.D. in biochemical engineering and his scientific work"

Biochemical engineering applies principles of chemistry, biology and engineering to design and scale processes that use living cells, enzymes or biological molecules to make products like drugs, enzymes, fuels and food ingredients. For investors, it matters because these processes determine how quickly and cheaply a product can be manufactured, the likelihood of meeting safety and regulatory standards, and therefore the company’s production costs, profit margins and ability to grow — like turning a kitchen recipe into a factory line.

securities analysis financial

"industry experience, and securities analysis that fits directly into our approach"

Securities analysis is the process of examining financial information, market trends, and other factors to estimate the value and risk of stocks, bonds or similar investments. It matters to investors because it’s like inspecting a used car before buying: it helps reveal whether a security is likely to gain or lose value, how risky it is, and whether it fits an investor’s goals and tolerance for loss.

AI-generated analysis. Not financial advice.

The addition of well-respected biotech expert strengthens one of Oppenheimer's longest-standing franchise areas

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.

Biliouris comes to Oppenheimer from BMO Capital Markets, where he was a Director, mainly covering the genetic medicines space. Before BMO, he was a VP in Biotech Research at Morgan Stanley and worked in drug development and product strategy at Novartis. His background includes a Ph.D. in biochemical engineering and his scientific work was published in collaboration with Biogen, Ionis, Merck, Novartis, and the FDA.

"Kostas brings a rare combination of scientific depth, industry experience, and securities analysis that fits directly into our approach to biotech equity research," Bird said. "His commercial mindset has been shaped by years of engagement with investors and corporate leaders, making him highly regarded by institutional and corporate clients. We are excited to expand Oppenheimer's research coverage of biotech, an area of rapid innovation and increasing focus for our clients. Kostas brings extraordinary experience and perspective and we are thrilled to have him onboard."

Oppenheimer provides coverage across the healthcare ecosystem, including biotechnology, pharmaceuticals, medical technology, and related sectors. The healthcare franchise has long been one of the firm's most established areas of expertise.

"I am excited to join Oppenheimer's research team and contribute to a platform known for its commitment to Healthcare and thoughtful industry coverage," Biliouris said. "The pace of innovation in genetic medicines and the broader biotech space continues to accelerate, and I look forward to working with colleagues to help make sense of these developments for the firm's clients."

About Oppenheimer Holdings Inc.
Oppenheimer Holdings Inc., through its Oppenheimer & Co. Inc. subsidiary, and related entities, provides a full range of wealth management, securities brokerage, and investment banking services to high-net-worth individuals, families, corporate executives, businesses, and institutions. For more information, please visit www.oppenheimer.com.

Media Contact:
Michael Dugan
Haven Tower Group LLC
424 317 4852
mdugan@haventower.com

View original content:https://www.prnewswire.com/news-releases/oppenheimer--co-inc-strengthens-equities-and-biotech-research-teams-with-addition-of-kostas-biliouris-phd-302632809.html

SOURCE Oppenheimer & Co. Inc.

FAQ

Who is Kostas Biliouris and what role did he join at Oppenheimer (OPY) on Dec. 8, 2025?

Kostas Biliouris joined Oppenheimer as Managing Director on the Biotech Research Team, reporting to William Bird and based in New York.

What is Kostas Biliouris's experience relevant to Oppenheimer's biotech coverage (OPY)?

He previously covered genetic medicines at BMO Capital Markets, was VP in biotech research at Morgan Stanley, and worked in drug development and product strategy at Novartis.

How does the December 8, 2025 hire affect Oppenheimer's (OPY) healthcare research coverage?

The firm says the hire strengthens its long-standing healthcare and biotech research franchise and expands expertise in genetic medicines and related sectors.

Will Kostas Biliouris's research at Oppenheimer (OPY) focus on genetic medicines?

Yes; his background and prior coverage emphasize the genetic medicines space and related biotech areas.

Who will Kostas Biliouris report to at Oppenheimer (OPY) and where is he based?

He will report to William (Bill) Bird, Director of Research, and is based in New York City.

How can investors follow Oppenheimer's (OPY) expanded biotech research after the hire?

Investors can monitor Oppenheimer research publications and coverage updates from the firm's healthcare research team for new reports and analyst commentary.